|
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to update Novartis Glivec (imatinib) label to include 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST). This extended treatment regimen has been shown to improve recurrence-free survival and overall survival for KIT+ GIST patients.
The CHMP opinion was based on data from a multicenter, open-label, phase III clinical trial. Results of the study, which were first presented in June 2011 at the American Society of Clinical Oncology plenary session, showed that at five years, 66 per cent of patients taking Glivec for three years after surgery for KIT+ GIST remained free of cancer recurrence (primary endpoint), compared to 48 per cent who had received Glivec for only one year after surgery (p<0.0001). In addition, at five years, 92 per cent of patients taking Glivec for three years after surgery were alive (secondary endpoint) compared to 82 per cent who had received Glivec for only one year after surgery (p=0.019).
Glivec (imatinib) is approved in more than 110 countries for the treatment of all phases of Ph+ CML, for the treatment of adult patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST), which cannot be surgically removed and/or have metastasized and for the treatment of adult patients following complete surgical removal of KIT+ GIST. Take with food and a large glass of water.
"This CHMP positive opinion marks another major milestone in the evolution of GIST treatment, which began almost a decade ago with the introduction of Glivec in the metastatic setting," said Hervé Hoppenot, president, Novartis Oncology.
Gastrointestinal stromal tumours are a rare, life-threatening cancer of the gastrointestinal tract. The major cause of GIST is an abnormal form of the protein KIT which causes cells to grow uncontrollably and become cancerous. Patients with KIT+ GIST are at risk of recurrence following complete resection of primary GIST.
Applications are also underway for Glivec label updates in the United States and worldwide. In addition, in August 2011 the US National Comprehensive Cancer Network (NCCN) updated its clinical practice guidelines to recommend consideration of at least three years of adjuvant therapy with Glivec for patients with high-risk GIST.
The SSG XVIII clinical trial was conducted by the Scandinavian Sarcoma Group (SSG) and the Sarcoma Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO). This trial was a multicenter, prospective, randomized study for the evaluation of adjuvant treatment with Glivec of histologically confirmed KIT+ GIST with an estimated risk of GIST recurrence of greater than 50% despite complete removal of all macroscopic GIST tissue at surgery.
The primary endpoint of the study was to compare, within the first five years, recurrence-free survival in patients with a greater than 50% estimated risk of GIST disease recurrence, following diagnosis and treatment with adjuvant Glivec for either 12 or 36 months. The secondary endpoints included overall survival and treatment safety.
Four hundred patients entered the study and the median follow-up was 54 months. Recurrence-free survival was longer in the 36-month group compared to the 12-month group (HR 0.46, 95% CI 0.32-0.65; p<0.0001; five-year recurrence-free survival 66% vs. 48%, respectively). Patients assigned to 36 months of Glivec after surgery had longer overall survival (HR 0.45, 95% CI 0.22-0.89; p=0.019; five-year overall survival 92% vs. 82%, respectively). Almost all patients experienced side effects while taking Glivec. Glivec was generally well tolerated. The proportion of patients who discontinued Glivec during the assigned treatment period for reasons other than GIST recurrence was 26% over the full 3 year treatment period in the 36-month group and 13% in the 12-month group.
Novartis provided the study drug and supported the study financially. Additional financing was received from the Academy of Finland, Cancer Society of Finland, Sigrid Juselius Foundation and Helsinki University Research Funds.
|